Ekso Bionics (EKSO) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Ekso Bionics (NASDAQ:EKSO) from a sell rating to a hold rating in a research note released on Tuesday morning.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Separately, ValuEngine raised shares of Ekso Bionics from a strong sell rating to a sell rating in a report on Friday, November 17th.

Shares of Ekso Bionics (NASDAQ:EKSO) traded down $0.07 during trading on Tuesday, reaching $1.95. 473,046 shares of the company’s stock traded hands, compared to its average volume of 1,047,263. The company has a market cap of $121.01, a price-to-earnings ratio of -2.10 and a beta of 2.01. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73. Ekso Bionics has a 12-month low of $0.99 and a 12-month high of $4.77.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $2.40 million. Ekso Bionics had a negative net margin of 343.53% and a negative return on equity of 323.00%. sell-side analysts forecast that Ekso Bionics will post -0.81 EPS for the current year.

In other Ekso Bionics news, insider Russ Angold sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total value of $175,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.32% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Intellectus Partners LLC grew its holdings in shares of Ekso Bionics by 5.3% in the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after purchasing an additional 5,294 shares during the last quarter. Carl Domino Inc grew its holdings in shares of Ekso Bionics by 125.2% in the 3rd quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock worth $224,000 after purchasing an additional 102,734 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Ekso Bionics by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after purchasing an additional 176,197 shares during the last quarter. Finally, National Planning Corp grew its holdings in shares of Ekso Bionics by 122.2% in the 3rd quarter. National Planning Corp now owns 520,942 shares of the company’s stock worth $620,000 after purchasing an additional 286,492 shares during the last quarter. 6.22% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Ekso Bionics (EKSO) Upgraded by Zacks Investment Research to “Hold”” was originally posted by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.themarketsdaily.com/2018/01/12/ekso-bionics-ekso-upgraded-by-zacks-investment-research-to-hold.html.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Get a free copy of the Zacks research report on Ekso Bionics (EKSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply